REG - Hikma Pharmaceutical - Total Voting Rights <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

01/11/2017 11:45

RNS Number : 2680V
Hikma Pharmaceuticals Plc
01 November 2017
Hikma Pharmaceuticals PLC 
Total Voting Rights and Capital
LONDON, 1 November 2017 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 October 2017, its share capital consists of 240,655,680 ordinary shares with voting rights. There are nil shares held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's DTR's. 
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2760


About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
TVREAFFFELDXFFF